- Home
- COF vs SNY Comparison
COF vs SNY Comparison
Compare COF & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COF
- SNY
- Stock Information
- Founded
- COF 1988
- SNY 1994
- Country
- COF United States
- SNY France
- Employees
- COF N/A
- SNY N/A
- Industry
- COF Major Banks
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- COF Finance
- SNY Health Care
- Exchange
- COF Nasdaq
- SNY Nasdaq
- Market Cap
- COF 144.9B
- SNY 116.1B
- IPO Year
- COF 1994
- SNY N/A
- Fundamental
- Price
- COF $213.73
- SNY $49.11
- Analyst Decision
- COF Buy
- SNY Buy
- Analyst Count
- COF 16
- SNY 4
- Target Price
- COF $243.13
- SNY $61.50
- AVG Volume (30 Days)
- COF 3.2M
- SNY 3.9M
- Earning Date
- COF 10-21-2025
- SNY 10-24-2025
- Dividend Yield
- COF 1.13%
- SNY 3.25%
- EPS Growth
- COF N/A
- SNY 118.56
- EPS
- COF N/A
- SNY 8.65
- Revenue
- COF $23,773,000,000.00
- SNY $53,714,621,258.00
- Revenue This Year
- COF $94.82
- SNY $1.53
- Revenue Next Year
- COF $18.43
- SNY $7.06
- P/E Ratio
- COF N/A
- SNY $5.69
- Revenue Growth
- COF N/A
- SNY 15.65
- 52 Week Low
- COF $143.22
- SNY $44.62
- 52 Week High
- COF $232.45
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- COF 39.70
- SNY 54.77
- Support Level
- COF $210.30
- SNY $44.62
- Resistance Level
- COF $217.21
- SNY $51.05
- Average True Range (ATR)
- COF 5.03
- SNY 0.83
- MACD
- COF -1.43
- SNY 0.43
- Stochastic Oscillator
- COF 25.16
- SNY 68.73
About COF Capital One Financial Corporation
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending. Following the acquisition of Discover in 2025, the firm also has a modest personal loan business, though credit card lending still provides the majority of the bank's revenue.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.